Praxis Precision Medicines (PRAX) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
10 Jun, 2026Opening remarks and agenda
Meeting commenced with introductions of board members and executive officers joining virtually.
Independent auditors from Ernst & Young LLP were introduced as present.
Agenda and rules of conduct were made available in the virtual portal, with instructions for voting and Q&A.
Board and executive committee updates
Board members and executive officers were introduced, including the CEO, CFO, COO, General Counsel, and SVP of Finance.
Shareholder proposals
Three proposals were presented: election of Class III directors, ratification of auditors, and advisory approval of executive compensation.
No advance notice of director nominations was received from shareholders.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Praxis Precision Medicines
- Ulixacaltamide targets a vast unmet need in essential tremor, with a major launch imminent.PRAX
Goldman Sachs 47th Annual Global Healthcare Conference 20268 Jun 2026 - Ulyxa and relumitragene advance toward launch with strong FDA continuity and broad commercialization plans.PRAX
TD Cowen 46th Annual Health Care Conference18 May 2026 - Expanding a diversified royalty portfolio with strong growth, high margins, and disciplined asset selection.PRAX
Bank of America Global Healthcare Conference 202613 May 2026 - FDA accepted two NDAs; $1.4B cash supports launches and late-stage readouts in 2026.PRAX
Q1 20267 May 2026 - Four late-stage CNS assets target blockbuster sales with two PDUFA dates in 2026–2027.PRAX
Corporate presentation7 May 2026 - 2026 proxy details director elections, auditor ratification, and strong pay-for-performance alignment.PRAX
Proxy filing30 Apr 2026 - Votes will be held on director elections, auditor ratification, and executive compensation.PRAX
Proxy filing30 Apr 2026 - Two NDA filings, strong clinical data, and $1.5B cash position set up multiple 2026 launches.PRAX
Q4 202519 Feb 2026 - Late-stage CNS pipeline targets >$20B revenue with strong efficacy, safety, and IP protection.PRAX
Corporate presentation19 Feb 2026